Marco Wong, M.D., Ph.D.

    Marco Wong, M.D., Ph.D.
    Medical Director
    Marco Wong, M.D., Ph.D., joined Proteon in 2006 and has served as our Medical Director since 2011, prior to which he was Associate Director of Research and Development from 2009 until 2011 and Physician Scientist/Senior Scientist from 2006 until 2009. Prior to joining Proteon, Dr. Wong served as a Post-doctoral Research Associate at the Stowers Institute for Medical Research from 2003 to 2006, where he conducted genetic and molecular analysis of stem cells and germ cell development. He holds a B.S. from California State University and an M.D. and Ph.D. from Wayne State University School of Medicine.

    Paul Hastings

    Paul J. Hastings
    Chairman of the Board of Directors Chairman and Chief Executive Officer, OncoMed Pharmaceuticals
    Paul Hastings has served as a member of our board of directors and its chairman since October 2016. Mr. Hastings is the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr. Hastings was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010), and served on the boards of ViaCell (sold to Perkin-Elmer in 2007), Cerimon Pharmaceuticals and Relypsa (sold to Galenica in 2016). He is currently on the board of Pacira Pharmaceuticals, serves as Vice Chairman of Biotechnology Innovation Organization, and is also on the board of directors of the California Life Sciences Association. Mr. Hastings received a B.S. in pharmacy from the University of Rhode Island.

    Garen Bohlin

    Garen Bohlin
    Consultant, Life Sciences and Healthcare Companies
    Garen Bohlin has served as a member of our board of directors since September 2014. Since May 2012, Mr. Bohlin has served as a consultant to various life sciences and healthcare companies. From January 2010 until April 2012, he served as Executive Vice President of Constellation Pharmaceuticals, a biopharmaceutical company. Prior to joining Constellation Pharmaceuticals, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, a biopharmaceutical company, from 2006 to December 2009. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., a biopharmaceutical company, from 1999 through December 2008. Earlier in his career, he held multiple executive positions at Genetics Institute, a biopharmaceutical company, and was a partner at Arthur Andersen & Co., a public accounting and consulting organization. Mr. Bohlin currently serves on the board of directors of Tetraphase Pharmaceuticals and Karyopharm Therapeutics, both NASDAQ listed, and Acusphere, Inc. He also served on the board of directors for Targanta Therapeutics from 2007 to 2009, SpringLeaf Therapeutics from 2010 to 2013 and Precision Dermatology from 2012 to July 2014. Mr. Bohlin received his B.S. in accounting and finance from The University of Illinois.
    Financial Expert

    Hubert Birner, Ph.D.

    Hubert Birner, Ph.D.
    Managing Partner, TVM Capital
    Hubert Birner, Ph.D., joined TVM Capital in 2000, and is responsible for TVM Capital Life Sciences’ overall investment strategy and the fund operations in North America and Europe. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina) and Spepharm Holding BV (Amsterdam, The Netherlands). Before joining TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. Dr. Birner was also an Assistant Professor for biochemistry at the Ludwig-Maximilian-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies. Dr. Birner holds an M.B.A. from Harvard Business School and a doctoral degree in biochemistry from Ludwig-Maximilian-University Munich, where he graduated summa cum laude. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.

    Tony Kingsley

    Tony Kingsley
    President and Chief Operating Officer, The Medicines Company
    Tony Kingsley has served as a member of our board of directors since October 2015. Mr. Kingsley joined The Medicines Company (MDCO) in May 2016 as President and Chief Operating Officer. Previously, he served as Executive Vice President, Global Commercial Operations at Biogen from November 2011 to October 2015. From January 2010 to November 2011, Mr. Kingsley served as Biogen’s Senior Vice President, U.S. Commercial Operations. Prior to that, he served as Senior Vice President and General Manager of the Gynecological Surgical Products business at Hologic, Inc., from October 2007 to November 2009, and as Division President, Diagnostic Products at Cytyc Corp., from July 2006 to October 2007. From 1991 to 2006, he was a Partner at McKinsey & Company, focusing on the biotechnology, pharmaceutical and medical device industries. Mr. Kingsley received a B.A. in government from Dartmouth College and an M.B.A. from Harvard Business School.

    Gregory Phelps

      Gregory D. Phelps
      Chairman of the Board; Partner, Red Sky Partners
      Gregory D. Phelps has been a member of our board of directors since 2008 and has served as Chairman of the Board since 2009. Mr. Phelps is an independent advisor to biotechnology and pharmaceutical companies. He was a founder and Partner of Red Sky Partners LLC, an advisory firm providing corporate development, product strategy and leadership support to life sciences companies, from 2009 to 2014. Prior to that, Mr. Phelps served as Chairman and Chief Executive Officer of RenaMed Biologics, Inc., a private biotechnology company developing a therapeutic treatment for Acute Kidney Injury, from 2004 to 2007. His previous executive management roles include Chief Executive Officer of Ardais Corporation (2002-2003), Vice Chairman and member of the executive committee of Dyax Corporation (1998-2002), Executive Vice President and Senior Vice President of Genzyme Corporation (1991-1997), Chief Executive Officer of Viagene, Inc. (1988-1990), Chief Executive Officer of ZymoGenetics, Inc. (1986-1988) and various management positions with Baxter Travenol Laboratories, Inc., now Baxter International, Inc. (1975-1986), most recently as Vice President. Mr. Phelps’ previous board directorships include Charles River School (2004-2011, board chairman 2008-2011), EPIX Pharmaceuticals Inc. (2004-2009), Ostex International Inc. (1995-2001), Atlantic Biopharmaceuticals, now Merrimack Pharmaceuticals Inc. (1998-2000), Neozyme II Corporation (1992-1996), Genzyme Transgenics Corporation, now rEVO Biologics (1993-1995) and the Hemophilia Foundation of California (1982-1984). Mr. Phelps received a B.S. in electrical engineering from Bradley University and an M.B.A. from Harvard Business School.

      Dmitry Kobyzev, Ph.D.

        Dmitry Kobyzev, Ph.D.
        Investment Manager, Inbio Ventures
        Dmitry Kobyzev, Ph.D., has been a member of our board of directors since 2014. Dr. Kobyzev joined Inbio Ventures, a venture capital management company representing Pharmstandard International, S.A., in 2014 and is an Investment and Portfolio Manager. From 2010 to 2014, he served as an Investment Director of one of the top Russian life science venture capital teams at RUSNANO OJSC, which has approximately $1 billion under management. From 2005 to 2010, Dr. Kobyzev advised international private equity and Russian corporate clients within the transactions practice at PricewaterhouseCoopers Russia. Dr. Kobyzev received a Ph.D. degree in economics from Moscow State University.

        Tim Haines

        Tim Haines
        Partner, Abingworth LLP
        Tim Haines has served as a member of our board of directors since 2014. Mr. Haines joined Abingworth in 2005 and is currently a partner. From 2000 to 2005, he was Chief Executive of Astex Therapeutics, an Abingworth portfolio company. From 1993 to 2000, Mr. Haines was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Current and past board positions include Astex Pharmaceuticals, Chroma, Fovea, Pixium Vision, PowderMed, Kspine, Stanmore Implants, Lombard Medical, Sientra, and XCounter. Mr. Haines received a B.Sc. from Exeter University and an M.B.A. from INSEAD.